'BioSimilar' Drug Retacrit (Epoetin Alfa-epbx) Approved to Treat Certain Types of Anemia

TUESDAY, May 15, 2018 — Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first “biosimilar” to the anemia drugs Epogen and Procrit.
A biosimilar, derived from a living organism, has been proven to be…
Source: Topamax